Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : LRMR save search
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: -3.28%
H: 5.23%
C: 3.45%
year update therapeutics financial results
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
Published: 2024-03-11 (Crawled : 20:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: 2.09%
H: 1.36%
C: -0.45%
first label extension therapeutics study
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: -0.44%
H: 2.77%
C: -2.41%
conference biopharma global therapeutics
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Published: 2024-02-16 (Crawled : 22:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
| Email alert
Add to watchlist
offering therapeutics
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
Published: 2024-02-14 (Crawled : 11:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: 24.03%
H: 19.18%
C: 10.33%
offering therapeutics
Larimar Therapeutics Announces Proposed Underwritten Public Offering
Published: 2024-02-13 (Crawled : 21:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: 24.03%
H: 19.18%
C: 10.33%
offering therapeutics
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia
Published: 2024-02-12 (Crawled : 12:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: -16.24%
H: 26.92%
C: 20.46%
positive therapeutics study
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: 0.42%
H: 16.25%
C: 6.67%
therapeutics financial results
Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference
Published: 2023-11-01 (Crawled : 20:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: -1.05%
H: 2.11%
C: 1.41%
conference immunology therapeutics
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
Published: 2023-10-03 (Crawled : 20:00) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -2.07%
H: 0.19%
C: -0.07%
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: -2.42%
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.0%
H: 0.03%
C: 0.02%
therapeutics
Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
Published: 2023-08-31 (Crawled : 20:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: 0.81%
H: 3.2%
C: 2.13%
conference biopharma therapeutics
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Published: 2023-08-10 (Crawled : 11:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: 2.25%
H: 0.0%
C: -6.85%
therapeutics financial results
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial
Published: 2023-07-25 (Crawled : 11:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: 0.64%
H: 10.79%
C: 6.98%
cti-1601 fda label clearance extension trial therapeutics
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
Published: 2023-07-17 (Crawled : 20:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: -0.31%
H: 2.49%
C: 0.62%
medical therapeutics
Larimar Therapeutics Set to Join Russell 3000® Index
Published: 2023-06-21 (Crawled : 20:00) - globenewswire.com
LDNXF | $114.532 -12.32% 1.3K
|
Finance
|
| O: -0.26%
H: 0.0%
C: -0.89%
LNSTY | $28.4758 0.53% 99K
|
Finance and Insurance
|
| O: -0.87%
H: 0.0%
C: -1.32%
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: 1.44%
H: 0.28%
C: -4.55%
3000 index set therapeutics
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results
Published: 2023-05-15 (Crawled : 11:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: -20.36%
H: 6.95%
C: -10.92%
therapeutics financial results
Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days
Published: 2023-03-28 (Crawled : 22:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: 0.45%
H: 4.98%
C: -0.9%
rare disease genomic therapeutics
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
Published: 2023-03-14 (Crawled : 11:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.14%
H: 0.49%
C: 0.42%
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: 4.36%
H: 0.67%
C: -1.34%
year therapeutics financial results
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
Published: 2023-02-07 (Crawled : 00:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.08%
H: 1.41%
C: 1.11%
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: 0.0%
H: 10.51%
C: 6.52%
therapeutics
Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601
Published: 2022-10-20 (Crawled : 13:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: 0.0%
H: 0.87%
C: -2.92%
cti-1601 patent therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
BTCM | $1.99 -6.13% 4.52% 75K
|
Arts, Entertainment, and Recrea...
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
UHS | $157.47 2.49% 4.13% 900K
|
Health Services
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.